{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:44:54Z","timestamp":1769906694408,"version":"3.49.0"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Current approaches to cancer immunotherapy include immune checkpoint inhibitors, cancer vaccines, and adoptive cellular therapy. These therapies have produced significant clinical success for specific cancers, but their efficacy has been limited. Oncolytic virotherapy (OVT) has emerged as a promising immunotherapy for a variety of cancers. Furthermore, the unique characteristics of OVs make them a good choice for delivering tumor peptides\/antigens to induce enhanced tumor-specific immune responses. The first oncolytic virus (OV) approved for human use is the attenuated herpes simplex virus type 1 (HSV-1), Talimogene laherparepvec (T-VEC) which has been FDA approved for the treatment of melanoma in humans. In this study, we engineered the recombinant oncolytic HSV-1 (oHSV) VC2-OVA expressing a fragment of ovalbumin (OVA) as a fusion protein with VP26 virion capsid protein. We tested the ability of VC2-OVA to act as a vector capable of stimulating strong, specific antitumor immunity in a syngeneic murine melanoma model. Therapeutic vaccination with VC2-OVA led to a significant reduction in colonization of tumor cells in the lungs of mice intravenously challenged B16cOVA cells. In addition, VC2-OVA induced a potent prophylactic antitumor response and extended survival of mice that were intradermally engrafted with B16cOVA tumors compared with mice immunized with control virus.<\/jats:p>","DOI":"10.3389\/fmolb.2022.832393","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T06:29:11Z","timestamp":1643178551000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Utility of a Recombinant HSV-1 Vaccine Vector for Personalized Cancer Vaccines"],"prefix":"10.3389","volume":"9","author":[{"given":"Ifeanyi Kingsley","family":"Uche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent A.","family":"Stanfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared S.","family":"Rudd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin G.","family":"Kousoulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J. F.","family":"Rider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7274","DOI":"10.1038\/sj.onc.1207947","article-title":"Self-renewal and Solid Tumor Stem Cells","volume":"23","author":"Al-Hajj","year":"2004","journal-title":"Oncogene"},{"key":"B2","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.4049\/jimmunol.0901466","article-title":"What Role Does the Route of Immunization Play in the Generation of Protective Immunity against Mucosal Pathogens","volume":"183","author":"Belyakov","year":"2009","journal-title":"J. Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.vaccine.2018.11.042","article-title":"The HSV-1 Live Attenuated VC2 Vaccine Provides protection against HSV-2 Genital Infection in the guinea Pig Model of Genital Herpes","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"key":"B4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1128\/cvi.00286-10","article-title":"Translating Tumor Antigens into Cancer Vaccines","volume":"18","author":"Buonaguro","year":"2011","journal-title":"Clin. Vaccin. Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/08830185.2015.1015888","article-title":"A New Era in Cancer Immunotherapy: Discovering Novel Targets and Reprogramming the Immune System","volume":"34","author":"Chiriva-Internati","year":"2015","journal-title":"Int. Rev. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7563","DOI":"10.1128\/jvi.72.9.7563-7568.1998","article-title":"Incorporation of the Green Fluorescent Protein into the Herpes Simplex Virus Type 1 Capsid","volume":"72","author":"Desai","year":"1998","journal-title":"J. Virol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nbt0209-129","article-title":"The Cancer Vaccine Roller Coaster","volume":"27","author":"Goldman","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/fimmu.2017.00800","article-title":"Sharpening the Edge for Precision Cancer Immunotherapy: Targeting Tumor Antigens through Oncolytic Vaccines","volume":"8","author":"Holay","year":"2017","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards Personalized, Tumour-specific, Therapeutic Vaccines for Cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1128\/JVI.02468-15","article-title":"Deletion of a Predicted \u03b2-Sheet Domain within the Amino Terminus of Herpes Simplex Virus Glycoprotein K Conserved Among Alphaherpesviruses Prevents Virus Entry into Neuronal Axons","volume":"90","author":"Jambunathan","year":"2015","journal-title":"J. Virol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/jco.2009.25.0597","article-title":"Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"Jco"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e127882","DOI":"10.1172\/jci.insight.127882","article-title":"New Epitopes in Ovalbumin Provide Insights for Cancer Neoepitopes","volume":"5","author":"Karandikar","year":"2019","journal-title":"JCI Insight"},{"key":"B13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2144\/000112096","article-title":"Two-step Red-Mediated Recombination for Versatile High-Efficiency Markerless DNA Manipulation in Escherichia coli","volume":"40","author":"Karstentischer","year":"2006","journal-title":"Biotechniques"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e01068","DOI":"10.1128\/JVI.01068-17","article-title":"Herpes Simplex Virus 1 Small Capsomere-Interacting Protein VP26 Regulates Nucleocapsid Maturation","volume":"91","author":"Kobayashi","year":"2017","journal-title":"J. Virol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1142\/s2339547818300020","article-title":"The Growing Role of Precision and Personalized Medicine for Cancer Treatment","volume":"6","author":"Krzyszczyk","year":"2018","journal-title":"Technology (Singap World Sci)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"8592","DOI":"10.1128\/jvi.00223-12","article-title":"Structural Variability of the Herpes Simplex Virus 1 GenomeIn VitroandIn Vivo","volume":"86","author":"Mahiet","year":"2012","journal-title":"J. Virol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0228252","DOI":"10.1371\/journal.pone.0228252","article-title":"Intramuscular Vaccination of Mice with the Human Herpes Simplex Virus type-1(HSV-1) VC2 Vaccine, but Not its Parental Strain HSV-1(F) Confers Full protection against Lethal Ocular HSV-1 (McKrae) Pathogenesis","volume":"15","author":"Naidu","year":"2020","journal-title":"PLoS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.3390\/cells9092056","article-title":"Precision Medicine: Steps along the Road to Combat Human Cancer","volume":"9","author":"Nassar","year":"2020","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1016\/j.celrep.2020.02.111","article-title":"Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity","volume":"30","author":"Ols","year":"2020","journal-title":"Cel Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/mt.2010.289","article-title":"Intradermal Vaccinations with RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients","volume":"19","author":"Rittig","year":"2011","journal-title":"Mol. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/j.cell.2021.02.055","article-title":"The Next Horizon in Precision Oncology: Proteogenomics to Inform Cancer Diagnosis and Treatment","volume":"184","author":"Rodriguez","year":"2021","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"645210","DOI":"10.3389\/fimmu.2021.645210","article-title":"Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-specific Immune Response","volume":"12","author":"Rosenbaum","year":"2021","journal-title":"Front. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"6386","DOI":"10.1158\/1078-0432.ccr-07-0486","article-title":"Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting","volume":"13","author":"Slingluff","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.vaccine.2016.12.018","article-title":"Vaccination of Rhesus Macaques with the Live-Attenuated HSV-1 Vaccine VC2 Stimulates the Proliferation of Mucosal T Cells and Germinal center Responses Resulting in Sustained Production of Highly Neutralizing Antibodies","volume":"35","author":"Stanfield","year":"2017","journal-title":"Vaccine"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1016\/j.vaccine.2018.03.075","article-title":"Intramuscular Vaccination of guinea Pigs with the Live-Attenuated Human Herpes Simplex Vaccine VC2 Stimulates a Transcriptional Profile of Vaginal Th17 and Regulatory Tr1 Responses","volume":"36","author":"Stanfield","year":"2018","journal-title":"Vaccine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e109890","DOI":"10.1371\/journal.pone.0109890","article-title":"A Single Intramuscular Vaccination of Mice with the HSV-1 VC2 Virus with Mutations in the Glycoprotein K and the Membrane Protein UL20 Confers Full Protection against Lethal Intravaginal Challenge with Virulent HSV-1 and HSV-2 Strains","volume":"9","author":"Stanfield","year":"2014","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The Landscape of Kinase Fusions in Cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat. Commun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1006732","DOI":"10.1371\/journal.ppat.1006732","article-title":"Influence of an Immunodominant Herpes Simplex Virus Type 1 CD8+ T Cell Epitope on the Target Hierarchy and Function of Subdominant CD8+ T Cells","volume":"13","author":"Treat","year":"2017","journal-title":"Plos Pathog."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e01359","DOI":"10.1128\/JVI.01359-20","article-title":"Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model","volume":"95","author":"Uche","year":"","journal-title":"J. Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3390\/v13071200","article-title":"The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment","volume":"13","author":"Uche","year":"","journal-title":"Viruses"},{"key":"B31","doi-asserted-by":"publisher","first-page":"eaai9339","DOI":"10.1126\/sciimmunol.aai9339","article-title":"Listening to Each Other: Infectious Disease and Cancer Immunology","volume":"2","author":"Vance","year":"2017","journal-title":"Sci. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1586\/14760584.2015.1081067","article-title":"Effect of Vaccine Administration Modality on Immunogenicity and Efficacy","volume":"14","author":"Zhang","year":"2015","journal-title":"Expert Rev. Vaccin."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2022.832393\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T06:29:13Z","timestamp":1643178553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2022.832393\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":32,"alternative-id":["10.3389\/fmolb.2022.832393"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2022.832393","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]},"article-number":"832393"}}